Background: Aminoglutethimide was the first aromatase inhibitor to be used successfully in breast cancer patients. However, this drug also inhibits mineralcorticoid and glucocorticoid synthesis, making co-medication with corticosteroids necessary, and it is often poorly tolerated. The primary objective of this trial was to evaluate the clinical efficacy and tolerability of vorozole, a new non-steroidal oral aromatase inhibitor, in postmenopausal breast cancer patients. The secondary objective was to evaluate the pharmacodynamic activity of the drug.
Introduction
Breast cancer is the most common cancer in females, accounting for 32% of all cancers and 18% of all cancer deaths in women [1] . Oestrogens are thought to promote the growth of hormone-sensitive breast carcinoma. Effective strategies in the endocrine treatment of breast cancer include either antagonizing the interaction of oestrogen with its receptor by using competitive antioestrogens, such as tamoxifen, or reducing the supply of oestrogens by inhibiting aromatase, the enzyme which catalyzes the conversion of androgens to oestrogens. In postmenopausal women the major source of circulating oestrogens is the peripheral aromatization of androgens, in particular androstenedione, by the cytochrome P450-regulated enzyme aromatase. Aminoglutethimide was the first aromatase inhibitor to be used in postmenopausal women with advanced breast cancer. It reduces circulating levels of oestrogens [2, 3] , and was shown to be clinically as effective as surgical adrenalectomy [4, 5] or tamoxifen [6] [7] [8] . However, aminoglutethimide also inhibits mineralcorticoid and glucocorticoid synthesis, thereby making co-medication with hydrocortisone necessary, and it is often poorly tolerated due to side effects including lethargy, drowsiness and skin rash. Thus, reasons for developing new aromatase inhibitors include the need for more specific aromatase inhibitors, i.e., not affecting other pathways of steroid synthesis or cytochrome co-factors in thyroid hormone synthesis, and the need for drugs that are well tolerated.
Vorozole is a third-generation, non-steroidal, oral aromatase inhibitor which has been shown to be 1000-fold more potent than aminoglutethimide in animal and human studies [9] . Previous studies with vorozole racemate (R076713) have shown that nearly all of the aromatase activity resides within the dextroenantiomer (R083842) [10, 11] . In vitro and in vivo animal studies have shown high potency and specificity [12] . In a study of 12 healthy postmenopausal women, a single oral dose of 1, 2.5, or 5 mg vorozole racemate resulted in 93%-94% inhibition of the in vivo conversion of androstenedione to oestrone [13] . In a phase I clinical study of vorozole racemate in postmenopausal women with advanced breast cancer, doses of 2.5 and 5 mg were well tolerated and resulted in suppression of oestradiol levels to below the detection limit of the assay (9.2 pmol/1) [14] . Objective as well as subjective responses (performance status, pain score) were observed in these heavily pretreated patients [15] .
The primary objective of this trial was to evaluate the clinical efficacy and tolerability of vorozole in postmenopausal patients with advanced breast cancer who relapsed after/during first-line or adjuvant hormonal therapy. The secondary objective was to evaluate the endocrine activity of the drug by assessing the relevant hormones.
Subjects and methods

Subject sample
Ambulatory female patients with histological diagnoses of carcinoma of the breast were admitted, provided they met the following criteria: age < 80 years; metastatic breast cancer with a first recurrence following or during adjuvant hormonal therapy (± adjuvant chemotherapy) with antioestrogens for at least one year, or progressive disease following a previous response (including no change for at least six months) to first-line treatment with tamoxifen for locally advanced or metastatic disease (in this case there had to be a treatment-free period of at least one week between discontinuation of hormonal therapy and entry into the trial); the presence of measurable or evaluable disease; postmenopausal status as defined by the absence of menstruation for 12 or more months after spontaneous or iatrogenic menopause; positive oestrogen receptor status, i.e., > 10 fmol/mg protein, or unknown status (if the oestrogen receptor status was unknown, a disease-free interval of at least two years had to have elapsed between the diagnosis and the development of progressive disease); life expectancy > 3 months; written informed consent.
Patients were excluded if they had one or more of the following: rapidly progressing, life-threatening metastases (brain or leptomeningeal disease, carcinomatose lymphangitis of the lung, or metastases of over one-third of the liver with abnormal liver function tests); ECOG performance status 3 or 4; significant renal (serum creatinine >l.5x upper limit of normal range) or hepatic (transaminases > 1.5 x upper limit of normal range, total bilirubin Jl.5x upper limit of normal range) dysfunction; significant haematological abnormalities (Hb < 10.5 g/dl, WBC <35OO/ul, or platelets <100000/ul); any concurrent or previous malignant disease within the past five years, except in situ carcinoma of the cervix or appropriately treated basal cell carcinoma of the skin; inability to comply with the protocol requirements (including mental or geographic impediments), or to respect adequate nutritional patterns or take trial medication correctly; proven hypersensitivity to imidazole drugs; current or prior participation (less than two months before start of the trial) in trials with another investigational drug.
Treatment
Vorozole was provided as 2.5 mg tablets. The drug was taken as one tablet, once daily. Treatment was to be discontinued if there was disease progression (UICC response criteria), if a serious toxicity occurred (WHO classification grades 3-4), or if the patient withdrew her consent. monthly thereafter, up to month 9 or until progression, for assessment of the effectiveness and safety of vorozole.
Objective evaluations
These included a complete physical examination, a chest X-ray, a bone scintigraphy (and a bone X-ray if the scintiscan was positive), a CT or ultrasound scan of the abdomen and routine haematological and biochemical laboratory tests. A chest X-ray was to be performed at month 2 and at progression. Patients presenting measurable metastases on chest X-ray were to have X-rays taken every two months. Patients with measurable or evaluable bone disease were to have a repeated bone X-ray every three months. A bone scintigraphy had to be repeated when progression occurred. Patients presenting measurable (liver) metastases on the CT or ultrasound scan had to have follow-up scans every two months. A CT or ultrasound scan of the abdomen had to be performed if clinical and/or biochemical signs suggested liver involvement by tumour in patients without liver metastasis at the beginning.
Performance status evaluations
The performance status was scored as follows (according to ECOG) at the start and at each visit: 0 = normal activity; 1 = symptomatic but ambulatory; 2 = confined to bed for less than 50% of time; 3 = confined to bed for 50% or more of time; 4 = confined to bed for 100% of time.
Adverse events and tolerability
Toxicity was evaluated at each visit on the basis of patient reports to their investigators regarding any kind of adverse event and of physical examinations based on WHO directives. If an adverse event not included in the WHO list was observed, a specific score was to be given for severity, as follows: 1 = mild; 2 = moderate; 3 = severe; 4 = lifethreatening. At each visit from week 1 onwards, the tolerability to vorozole was to be scored as follows: excellent, good, moderate, poor or unbearable.
Hormonal assessments
The following evaluations were made: oestradiol, oestrone, androstenedione, dehydroepiandrosterone (DHEA), cortisol, aldosterone, follicle-stimulating hormone (FSH), luteinizing hormone (LH). Blood samples were always to be taken at the same time of day, i.e., before ingestion of the trial medication in the morning. The samples (10 ml) were collected in heparinized test tubes and centrifuged for 10 minutes at 2500 r.p.m. (1000 g) within two hours of collection. Plasma samples were kept at -20 °C. Hormonal assays were carried out at the Janssen Research Foundation Laboratories in Beerse (Belgium). Oestrone and its tetradeuterated internal standard were extracted from plasma at neutral pH using diethyl ether. After an additional column purification, the residue was acylated using trifluoroacetic acid anhydride (TFA) and analyzed by gas chromatography coupled with high resolution mass spectrometry. The mass spectrometer was set to monitor the accurate molecular mass of oestrone-TFA and 2H4-oestrone-TFA. For oestradiol, a double antibody radioimmunoassay using iodinated oestradiol (Diagnostic Products Corporation, Belgium) was used. For the other hormones, a specific radioimmunoassay was used.
Drug concentration measurements
A blood sample was taken at each visit for the measurement of the plasma concentration of vorozole. The plasma concentrations were measured by gas chromatography with electron capture detection as previously described [16] .
Assessments
At the first visit, the patients were examined and baseline assessments were performed. The patients were to return at weeks 1-4, and
Statistical analysis
The main analysis was of intent-to-treat. The main efficacy parameter was objective response rate and the secondary efficacy parameters were: time to and duration of response, time to progression and survival time. Response to treatment was evaluated monthly using the UICC criteria [17] . In summary, a complete response (CR) was defined by the disappearance of all known manifestations of the disease, confirmed by two observations not less than four weeks apart; a partial response (PR) was defined by a 50% or more decrease in total tumour size of the lesions that have been confirmed by two observations not less than four weeks apart; no change (NQ was defined by a decrease of 50% or less or a less than 25% increase of tumour, confirmed by two observations not less than four weeks apart. Progressive disease (PD) was defined by a 25% or more increase in the size of measurable lesions or by the appearance of new lesions.
The following criteria for bone metastases were used: a PR was defined by the decrease in size of lytic lesions, recalcification of lytic lesions or decreased density of blastic lesions for at least four weeks. Due to the slow response of bone lesions, the definition of NC was not to be applied until at least eight weeks after therapy was started; PD was defined by the increase in size of existing lesions or the appearance of new lesions.
The overall response assessment was as follows, in patients with measurable disease, the poorest response designation prevailed; if in the total number of the responses by organ site there were equal or greater numbers of CR plus PR than NC, then overall response was PR; if PD was found in any lesion or when a new lesion appeared the overall result was PD; mixed responses with a progressive site were considered PD but the response per site had to be documented; progression in non-measurable lesions leading to definite deterioration of the patient due to tumour bulk was to be taken as an indication of progression regardless of what happened in the measurable disease site. Time to and duration of response, time to progression and survival time were calculated from trial entry using the Kaplan-Meier producthmit method [18] .
Sample size
The sample size was calculated on the basis of the percentage of objective responses. To be of clinical significance an objective response in not less than 10% of the sample had to be obtained. On the basis of R. Simon's two-stage 'optimal'design [19] (pO = 10%, pi = 30%, type I error = 0.05 and type II error = 0.10) 18 patients had to be enrolled in the first phase of the trial. If at least three objective responses were observed in these patients a further 17 were to be enrolled, for an overall total of 35 patients. If 7 of 35 (20%) responses or more were observed in the overall group, the hypothesis regarding the activity of the drug was to be accepted.
Results
The trial began on January 28, 1993 and included data obtained up to May 15, 1996 , at which date two patients were still being treated with vorozole. Eight centres participated, recruiting a total of 34 patients. A total of 31 patients reached end point: two patients progressed before the first scheduled assessment for the evaluation of response (two months), 27 patients reached end point for progression alone and two for a combination of adverse events and progression. Three patients dropped out of the trial, i.e., did not reach end point: one patient withdrew her consent on day 16 and two additional patients discontinued the trial after seven days and 10 months because of adverse events.
The main charactersitics of the study patients are summarized in Table 1 . Thirty-two patients had been pretreated with tamoxifen either as adjuvant or front- 
Efficacy results
Objective response
Four patients could not be assessed for response (i.e., were not evaluable) because they either completed or dropped out early: two patients had early disease progression, one patient dropped out due to adverse events and one patient withdrew her consent. There were seven responders, one complete and six partial. When the patients for whom data was missing were considered as non-responders (intent-to-treat analysis), the response rate was 21% (95% CI 9%-38%); when these patients were excluded from the response analysis (evaluable patient analysis), the response rate was 23% (95% CI 10%-42%). Of the seven responding patients, one had dominant bone disease, four had dominant visceral disease (two patients in the liver, one patient in the lung and one patient in the mediastinal lymphnodes) and two had dominant soft tissue disease. The patient achieving a CR and one of the partial responders had progressed during previous adjuvant treatment with tamoxifen after 41 and 25 months, respectively. All of the other responding patients had received prior tamoxifen treatment for their metastatic disease. Three had responded to front-line treatment and two were stable for six months or longer. The median time to first response was two months (95% CI 0.9^.5). The median duration of response was 9.6 months (95% CI 4.6-0). Fourteen patients showed stable disease (NQ with a median duration of 3.4 months (95% CI 2-8.8) but five patients (three with dominant visceral disease and two with dominant bone disease) were stable for at least six months (median NC duration in these patients: 15 months; range 10-43+ months). Eleven patients progressed, including the two who had early progression. The median time to progression of the group as a whole was 4.7 months (95% CI 2.9-6.6) and the median survival time was 29.7 months (95% CI 19.1-0). Overall there were 16 evaluable soft tissue sites, including breast lesions. Objective response was observed in eight (two CR and six PR) and NC was recorded in seven. Out of the 12 evaluable bone sites, one responded objectively to treatment and five were stable. Of the 15 evaluable visceral sites, four responded to treatment (one CR and three PR) and seven remained stable.
Hormone levels
Baseline oestradiol levels, mean 15.7 pmol/1 (±4.1), were suppressed to the detection limit of the radio-immunoassay (9.2 pmol/1), or a decrease of 42%, as long as treatment was maintained, i.e., up to 14 months in two patients. Oestrone levels were significantly reduced from 28.5 pg/ml (±4.5) mean value to or lower than 2.5 pg/ml (i.e., the detection limit of the gas chromatography mass spectometry assay), i.e., a decrease of 91%. No changes were detected in androstenedione, DHEA, LH, FSH, cortisol or aldosterone levels (data not shown).
Plasma levels
The overall median (range) plasma concentration of vorozole during the treatment period was 38.5 (^1.0-170) ng/ml which was within the range of vorozole steady-state concentration as seen in postmenopausal breast cancer patients in a formal pharmacokinetic trial [20] .
Safety results
Tolerability to treatment
At end point tolerability was excellent in 19 (61%) patients, good in 11 (36%) and moderate in one (3%). The mean scores changed very little during the trial: from 0.3 at week 1 to 0.4 at end point.
Adverse events
During the trial, 24 patients (71%) reported adverse events. Even though pain was reported as an adverse event for 15 patients (44%), none were considered as drug- related. For 16 adverse events (reported by 11 patients), a drug relationship was reported, i.e., 15 possible; one yes, i.e., for neuropathy. Table 2 summarizes the adverse events for which a drug relationship was reported.
Four patients permanently stopped the treatment due to adverse events of which just one, i.e., neuropathy, was drug-related. While the patient who developed neuropathy is still alive, the three patients who developed drug-unrelated adverse events subsequently died because of them.
Clinical laboratory evaluations
All patients had laboratory data available and of these, 28 patients had paired data, i.e., at baseline and at least once during treatment. Overall, there were no significant shifts in any of the laboratory parameters (data not shown).
There were no clinically significant changes in vital signs or weight during the trial (data not shown).
Discussion
Tamoxifen is an established treatment for postmenopausal women with locally advanced or metastatic breast cancer [21] . This drug is also effective in patients with early breast cancer [22] and it is widely used as adjuvant therapy following mastectomy [23] . Unfortunately, virtually all patients with advanced disease and most of those who receive adjuvant tamoxifen treatment develop tamoxifen resistance and progress or recur during tamoxifen treatment. All of these women require effective palliation of their disease. Progestins and aminoglutethimide are the drugs most commonly used to manage patients failing first-line or adjuvant tamoxifen treatment. These drugs show a definite therapeutic activity in these patients, but they are not devoid of serious side effects when they are used at high doses [24, 25] .
The clinical experience with vorozole as second-line treatment of patients failing tamoxifen therapy is still limited. Johnston et al. [26] evaluated the efficacy of three different daily doses of vorozole of 1, 2.5 and 5 mg. Twenty-four postmenopausal women with locally advanced or metastatic breast cancer who had responded to previous tamoxifen treatment were admitted to this study. Response to treatment was established according to UICC criteria [17] . Overall, eight patients (33%) had a PR and 10 further ones (42%) showed NC in their disease. No objective responses were observed in metastatic lesions to bone, liver or lung in this study. However, the number of patients with indicator lesions for these sites was very low. Treatment was well tolerated, particularly at the lowest doses. Twenty-nine postmenopausal patients were included into a subsequent study and were treated with a fixed dose of vorozole equal to 2.5 mg daily until disease progression [26] . The lower number of objective responses observed in these patients (three in 27 evaluable patients) is probably due to the fact that patients failing prior tamoxifen therapy were allowed to enter the study even when no previous response was documented and regardless of how long they had been treated with the antioestrogen. Per day 2.5 mg vorozole was also the dose employed by Paridaens et al. [27] in 27 postmenopausal patients with prior response to tamoxifen treatment for the metastatic disease or without evidence of disease progression for at least one year during adjuvant treatment with this antioestrogen. Objective responses according to UICC criteria [17] occurred in eight such patients (29%), mainly at the soft tissue or lung level.
In this trial, vorozole was administered to a group of postmenopausal breast cancer patients, all of whom had been pretreated with tamoxifen. Vorozole was able to induce durable objective responses in seven of the 34 (21%) patients admitted to this study. Thus, the hypothesis for the activity of vorozole was validated. The median time to response was established as at around two months and lasted 9.6 months (i.e., median time). In addition, 14 patients showed stable disease and five of them were stable for at least six months. Although just one PR was recorded at bone level, five of the 12 patients with dominant bone disease were stable two months after treatment start (two patients for more than six months). Because it was previously shown in breast cancer patients that NC for six months or longer predicts for survival as does PR, especially if NC occurs at bone level [29] , it appears that more than one-third of our patients (12 of 34) have benefited from vorozole treatment. Vorozole was very well tolerated, with an excellent-to-good score in 97% of the patients. A total of 14 patients died, two of them within 30 days of ending the treatment; both deaths were linked to progression. Most laboratory abnormalities were attributable to the course of the underlying disease.
During vorozole treatment (2.5 mg once daily) a high level of oestrogen suppression was maintained. The suppressive effect of treatment was more evident for oestrone than for oestradiol. However, this difference can probably be related to the low sensitivity of the radioimmunoassay used to measure oestradiol levels. In our study no interference with adrenocortical steroid synthesis by vorozole was observed. Although a more appropriate evaluation would have required measurements also after ACTH administration, the specificity of aromatase inhibition of vorozole is confirmed by previous studies on pharmacodynamics [9, [12] [13] [14] [15] . Therefore, it seems to us that present hormonal results and those previously reported illustrate the potency and selectivity of this third-generation aromatase inhibitor.
In conclusion, our results and those reported in the literature suggest that vorozole is a safe and effective drug for advanced breast cancer patients failing prior tamoxifen treatment. In these patients, vorozole seems to be at least as effective as and possibly better tolerated than other established treatments, including high-dose progestins and aminoglutethimide.
